Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Stake Boosted by Inceptionr LLC

Inceptionr LLC boosted its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 21.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,273 shares of the medical device company’s stock after purchasing an additional 1,478 shares during the period. Inceptionr LLC’s holdings in Tandem Diabetes Care were worth $298,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Assetmark Inc. acquired a new position in Tandem Diabetes Care in the 3rd quarter valued at approximately $29,000. Crossmark Global Holdings Inc. bought a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at approximately $200,000. State of New Jersey Common Pension Fund D increased its holdings in Tandem Diabetes Care by 24.6% in the third quarter. State of New Jersey Common Pension Fund D now owns 44,776 shares of the medical device company’s stock worth $1,899,000 after buying an additional 8,837 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Tandem Diabetes Care during the third quarter valued at approximately $263,000. Finally, Victory Capital Management Inc. grew its position in Tandem Diabetes Care by 45.6% in the third quarter. Victory Capital Management Inc. now owns 587,247 shares of the medical device company’s stock worth $24,905,000 after acquiring an additional 183,877 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Robert W. Baird reduced their price objective on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. Wells Fargo & Company reiterated an “equal weight” rating and set a $22.00 price target (down previously from $38.00) on shares of Tandem Diabetes Care in a research note on Monday, March 3rd. The Goldman Sachs Group cut their price objective on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Sanford C. Bernstein cut Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. Finally, Morgan Stanley downgraded Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $45.00 to $22.00 in a report on Wednesday, March 5th. Eight equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $45.38.

Tandem Diabetes Care Stock Down 4.1 %

TNDM stock opened at $17.96 on Monday. The business’s 50-day simple moving average is $33.17 and its 200 day simple moving average is $35.46. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The company has a market cap of $1.19 billion, a PE ratio of -9.31 and a beta of 1.45. Tandem Diabetes Care, Inc. has a twelve month low of $17.92 and a twelve month high of $53.69.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.